As an autoimmune disease, alopecia areata can include unpredictable periods of hair loss and regrowth. It can be frustrating ...

A national nonprofit supporting women of color affected by breast cancer will host its signature survivorship conference in ...

Even though Arvinas and Pfizer appear to have "written off" the drug, in one analyst's view, Rigel believes it can drive adoption among community-treated patients lacking SERD access.

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and ...

Pfizer's acquired products delivered $3.1 billion in Q1 revenue with 22% operational growth. Click here to read why I rate ...

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Pfizer (PFE +0.85%) stock reached all-time highs earlier this decade thanks to the company's dominance in the market for ...

Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently ​approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved ...

Arvinas and Pfizer have chosen Rigel Pharmaceuticals to bring their recently approved breast-cancer drug Veppanu to market.